Miami Breast Cancer Symposium to explore treatment controversies

Sessions will explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy.

FROM MBCC (FRONTLINE MEDICAL NEWS) – Oncology Practice will be on site this coming week at the Miami Breast Cancer Symposium in Miami Beach, reporting on the latest in multidisciplinary management of breast cancer patients. Sessions will highlight updates in systemic therapy, immunology and immunotherapy, and overcoming therapeutic resistance, as well as explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy. The symposium, hosted by Physicians’ Education Resource, begins Thursday, March 9. Our team will provide daily coverage of the following presentations and more:
 

Overcoming Resistance to HER2 Targeted Therapy

Mark D. Pegram, MD



Overcoming Resistance to Endocrine Ablative Therapy

William J. Gradishar, MD



Medical Crossfire: Is Extended Field Radiation Therapy Ready for Prime Time?

Lawrence J. Solin, MD, & Thomas A. Buchholz, MD



Raising the Therapeutic Index for HER2+ Targeted Therapy: Can We Safely Omit

Anthracyclines?

Sara Hurvitz, MD



Update on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

Debu Tripathy, MD



Update on PARP Inhibitors in Breast Cancer

Kimberly L. Blackwell, MD



Update on Immunology and Immunotherapy in Breast Cancer

Elizabeth Mittendorf, MD, PhD



Medical Crossfire: Is Extended Hormonal Therapy Required for Everyone?

William J. Gradishar, MD, & Sara Hurvitz, MD

Sessions will explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy.

FROM MBCC (FRONTLINE MEDICAL NEWS) – Oncology Practice will be on site this coming week at the Miami Breast Cancer Symposium in Miami Beach, reporting on the latest in multidisciplinary management of breast cancer patients. Sessions will highlight updates in systemic therapy, immunology and immunotherapy, and overcoming therapeutic resistance, as well as explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy. The symposium, hosted by Physicians’ Education Resource, begins Thursday, March 9. Our team will provide daily coverage of the following presentations and more:
 

Overcoming Resistance to HER2 Targeted Therapy

Mark D. Pegram, MD



Overcoming Resistance to Endocrine Ablative Therapy

William J. Gradishar, MD



Medical Crossfire: Is Extended Field Radiation Therapy Ready for Prime Time?

Lawrence J. Solin, MD, & Thomas A. Buchholz, MD



Raising the Therapeutic Index for HER2+ Targeted Therapy: Can We Safely Omit

Anthracyclines?

Sara Hurvitz, MD



Update on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

Debu Tripathy, MD



Update on PARP Inhibitors in Breast Cancer

Kimberly L. Blackwell, MD



Update on Immunology and Immunotherapy in Breast Cancer

Elizabeth Mittendorf, MD, PhD



Medical Crossfire: Is Extended Hormonal Therapy Required for Everyone?

William J. Gradishar, MD, & Sara Hurvitz, MD

Sessions will explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy.

FROM MBCC (FRONTLINE MEDICAL NEWS) – Oncology Practice will be on site this coming week at the Miami Breast Cancer Symposium in Miami Beach, reporting on the latest in multidisciplinary management of breast cancer patients. Sessions will highlight updates in systemic therapy, immunology and immunotherapy, and overcoming therapeutic resistance, as well as explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy. The symposium, hosted by Physicians’ Education Resource, begins Thursday, March 9. Our team will provide daily coverage of the following presentations and more:
 

Overcoming Resistance to HER2 Targeted Therapy

Mark D. Pegram, MD



Overcoming Resistance to Endocrine Ablative Therapy

William J. Gradishar, MD



Medical Crossfire: Is Extended Field Radiation Therapy Ready for Prime Time?

Lawrence J. Solin, MD, & Thomas A. Buchholz, MD



Raising the Therapeutic Index for HER2+ Targeted Therapy: Can We Safely Omit

Anthracyclines?

Sara Hurvitz, MD



Update on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

Debu Tripathy, MD



Update on PARP Inhibitors in Breast Cancer

Kimberly L. Blackwell, MD



Update on Immunology and Immunotherapy in Breast Cancer

Elizabeth Mittendorf, MD, PhD



Medical Crossfire: Is Extended Hormonal Therapy Required for Everyone?

William J. Gradishar, MD, & Sara Hurvitz, MD